These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
915 related items for PubMed ID: 16160130
1. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME, TAXUS V Investigators. JAMA; 2005 Sep 14; 294(10):1215-23. PubMed ID: 16160130 [Abstract] [Full Text] [Related]
6. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, Turco M, Caputo R, Bergin PJ, Bowman TS, Baim DS, TAXUS IV Investigators. JACC Cardiovasc Interv; 2009 Dec 14; 2(12):1248-59. PubMed ID: 20129552 [Abstract] [Full Text] [Related]
7. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schühlen H, Schmitt C, Dirschinger J, Schömig A, ISAR-DESIRE Study Investigators. JAMA; 2005 Jan 12; 293(2):165-71. PubMed ID: 15644543 [Abstract] [Full Text] [Related]
8. Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial). Nikolsky E, Kosinski E, Mishkel GJ, Kimmelstiel C, McGarry TF, Mehran R, Leon MB, Russell ME, Ellis SG, Stone GW. Am J Cardiol; 2005 Mar 15; 95(6):709-15. PubMed ID: 15757595 [Abstract] [Full Text] [Related]
9. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell ME, TAXUS VI Investigators. Circulation; 2005 Nov 22; 112(21):3306-13. PubMed ID: 16286586 [Abstract] [Full Text] [Related]
11. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G, Bonizzoni E, Colusso S, Repetto M, Merlini PA, SES-SMART Investigators. JAMA; 2004 Dec 08; 292(22):2727-34. PubMed ID: 15585732 [Abstract] [Full Text] [Related]
15. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. Holmes DR, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SA, SISR Investigators. JAMA; 2006 Mar 15; 295(11):1264-73. PubMed ID: 16531619 [Abstract] [Full Text] [Related]
16. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL, SPIRIT III Investigators. Circulation; 2009 Feb 10; 119(5):680-6. PubMed ID: 19171853 [Abstract] [Full Text] [Related]